*2.3. Peptides*

The peptide vaccine included HLA-A2402-restricted epitopes for four GOAs (LY6K, DEPDC1, KIF20A, and FOXM1) and two GAAAs (VEGFR1 and VEGFR2). These peptide epitopes have been previously identified and evaluated for safety and potent immunogenicity in various cancer patients: a VEGFR1-derived peptide (VEGFR1-1084; SYGVLLWEI) [29], a VEGFR2-derived peptide (VEGFR2-169; RFVPDGNRI) [30], a LY6K-derived peptide (LY6K-177; RYCNLEGPPI) [31], a DEPDC1-derived peptide (DEPDC1-294; EYYELFVNI) [16], a KIF20A-derived peptide (KIF20A-66; KVYLRVRPLL) [32], and a FOXM1-derived peptide (FOXM1-262; IYTWIEDHF) [33]. All GMP-grade peptides were synthesized by the American Peptide Company (Sunnyvale, CA, USA) according to a standard solid-phase synthesis method and purified by reversed-phase high-performance liquid chromatography (HPLC). The purity (>90%) and identity of the peptides were determined by analytical HPLC and mass spectrometry analysis, respectively.
